|
GB9206757D0
(en)
|
1992-03-27 |
1992-05-13 |
Ferring Bv |
Novel peptide receptor ligands
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
WO1997033603A1
(en)
|
1996-03-13 |
1997-09-18 |
Trustees Of The University Of Pennsylvania |
Novel peptides which inhibit complement activation
|
|
US6653340B1
(en)
|
1997-06-03 |
2003-11-25 |
Biocryst Pharmaceuticals, Inc. |
Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
|
|
EP1072263A4
(en)
|
1998-03-26 |
2004-03-31 |
Japan Tobacco Inc |
AMID DERIVATIVES AND NOCICEPTINANT AGONISTS
|
|
ATE246197T1
(de)
|
1998-09-09 |
2003-08-15 |
Metabasis Therapeutics Inc |
Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
|
|
KR20000047461A
(ko)
|
1998-12-29 |
2000-07-25 |
성재갑 |
트롬빈 억제제
|
|
WO2001017980A1
(en)
|
1999-09-03 |
2001-03-15 |
Ajinomoto Co., Inc. |
Novel processes for preparing oxazepine derivatives
|
|
US7528165B2
(en)
|
2001-12-13 |
2009-05-05 |
National Health Research Institutes |
Indole compounds
|
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
|
DE60326473D1
(en)
|
2002-07-16 |
2009-04-16 |
Amura Therapeutics Ltd |
Pyrrolderivate als hemmstoffe von cystein proteasen
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
PT1549333E
(pt)
|
2002-09-20 |
2012-01-03 |
Univ Pennsylvania |
Análogos de compstatina com actividade melhorada
|
|
FR2845382A1
(fr)
|
2002-10-02 |
2004-04-09 |
Sanofi Synthelabo |
Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
|
|
US7632858B2
(en)
|
2002-11-15 |
2009-12-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
|
AU2003902946A0
(en)
|
2003-06-12 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
ES2432112T3
(es)
|
2004-02-10 |
2013-11-29 |
The Regents Of The University Of Colorado, A Body Corporate |
Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
|
|
JP5032299B2
(ja)
|
2004-03-24 |
2012-09-26 |
シャイア・オーファン・セラピーズ・ゲーエムベーハー |
血管形成を阻害する新規化合物及びその使用
|
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
|
WO2006012373A2
(en)
|
2004-07-20 |
2006-02-02 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
ES2390828T3
(es)
|
2005-11-28 |
2012-11-16 |
The Trustees Of The University Of Pennsylvania |
Análogos potentes de la compstatina
|
|
BRPI0619733A2
(pt)
|
2005-12-12 |
2011-10-11 |
Genelabs Tech Inc |
compostos antivirais de n-(anel aromático de 6 membros)-amido
|
|
PL3167888T3
(pl)
|
2006-03-15 |
2024-08-26 |
Alexion Pharmaceuticals, Inc. |
Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
|
|
JPWO2008047831A1
(ja)
|
2006-10-17 |
2010-02-25 |
協和発酵キリン株式会社 |
Ｊａｋ阻害剤
|
|
CA2674865A1
(en)
|
2007-01-15 |
2008-07-24 |
Santen Pharmaceutical Co., Ltd. |
Indole derivative having i.kappa.b kinase .beta. inhibitory activity
|
|
PL2148691T3
(pl)
|
2007-02-05 |
2015-12-31 |
Apellis Pharmaceuticals Inc |
Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
|
|
ES2389994T3
(es)
|
2007-12-24 |
2012-11-05 |
Janssen R&D Ireland |
Indoles macrocíclicos como inhibidores del virus de la hepatitis C
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
GB2469471B
(en)
|
2009-04-14 |
2015-01-14 |
Skype |
Optimising communications
|
|
PL2424557T3
(pl)
|
2009-05-01 |
2018-04-30 |
The Trustees Of The University Of Pennsylvania |
Zmodyfikowana kompstatyna z modyfikacjami szkieletu peptydowego i c-końca
|
|
US9291622B2
(en)
|
2009-05-21 |
2016-03-22 |
Apellis Pharmaceuticals, Inc. |
Complement assays and uses thereof
|
|
CA2777013A1
(en)
|
2009-10-16 |
2011-04-21 |
Mochida Pharmaceutical Co., Ltd. |
Marker associated with non-alcoholic steatohepatitis
|
|
MX2012005151A
(es)
|
2009-11-05 |
2012-08-23 |
Federico Ii University Of Naples |
Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
|
|
EP3795573B1
(en)
|
2009-12-31 |
2022-07-06 |
Hutchison Medipharma Limited |
Certain triazolopyrazines, compositions thereof and methods of use therefor
|
|
PH12012502079A1
(en)
|
2010-04-16 |
2013-02-11 |
Ac Immune Sa |
Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
|
|
US9421240B2
(en)
|
2010-06-22 |
2016-08-23 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
US20130324482A1
(en)
|
2010-07-09 |
2013-12-05 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
|
|
EP2661433B1
(en)
|
2011-01-04 |
2017-08-16 |
Novartis AG |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
|
|
CN103687867B
(zh)
|
2011-05-11 |
2017-02-08 |
阿佩利斯制药公司 |
细胞反应性的、长效的或靶向的坎普他汀类似物及其用途
|
|
KR101931311B1
(ko)
|
2011-05-27 |
2018-12-20 |
아칠리온 파르마세우티칼스 인코포레이티드 |
Ｈｃｖ 감염 치료에 유용한 치환된 앨리팬, 시클로팬, 헤테라팬, 헤테로팬, 헤테로-헤테라팬 및 메탈로센
|
|
CA2877474A1
(en)
|
2011-06-20 |
2012-12-27 |
Myrexis, Inc. |
Compounds and therapeutic uses thereof
|
|
CN103796667A
(zh)
|
2011-06-22 |
2014-05-14 |
艾普莱斯制药公司 |
用补体抑制剂治疗慢性障碍的方法
|
|
US20130035392A1
(en)
|
2011-08-01 |
2013-02-07 |
Mcgeer Patrick L |
Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
|
|
CN110229216B
(zh)
|
2011-09-07 |
2023-06-16 |
宾夕法尼亚州大学理事会 |
具有改善的药代动力学性质的坎普他汀类肽
|
|
NZ742005A
(en)
|
2012-05-03 |
2019-04-26 |
Kala Pharmaceuticals Inc |
Pharmaceutical nanoparticles showing improved mucosal transport
|
|
US9056874B2
(en)
|
2012-05-04 |
2015-06-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
EP2855456B1
(en)
|
2012-05-04 |
2017-03-29 |
Novartis AG |
Complement pathway modulators and uses thereof
|
|
KR102339315B1
(ko)
|
2012-06-18 |
2021-12-15 |
오메로스 코포레이션 |
다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
|
|
JP6163205B2
(ja)
|
2012-06-20 |
2017-07-12 |
ノバルティス アーゲー |
補体経路モジュレーターおよびその使用
|
|
US9579360B2
(en)
|
2012-06-20 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
ES2644700T3
(es)
|
2012-06-28 |
2017-11-30 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
|
|
EP2867222A1
(en)
|
2012-06-28 |
2015-05-06 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
JP6273274B2
(ja)
|
2012-06-28 |
2018-01-31 |
ノバルティス アーゲー |
補体経路モジュレーターおよびその使用
|
|
WO2014002054A1
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
JP6214647B2
(ja)
|
2012-06-28 |
2017-10-18 |
ノバルティス アーゲー |
補体経路モジュレーターおよびその使用
|
|
CN104379579B
(zh)
|
2012-06-28 |
2017-03-08 |
诺华股份有限公司 |
吡咯烷衍生物及其作为补体途径调节剂的用途
|
|
ITMI20121156A1
(it)
|
2012-06-29 |
2013-12-30 |
Consiglio Nazionale Ricerche |
Metodo di elaborazione di immagini di tomografia a coerenza ottica
|
|
WO2014005150A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
|
|
WO2014002059A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
|
|
WO2014009833A2
(en)
|
2012-07-12 |
2014-01-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
MX2015002954A
(es)
|
2012-09-10 |
2015-06-05 |
Hoffmann La Roche |
Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b.
|
|
WO2014078734A2
(en)
|
2012-11-15 |
2014-05-22 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
ES2879430T3
(es)
|
2012-11-15 |
2021-11-22 |
Apellis Pharmaceuticals Inc |
Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
|
|
US9773428B2
(en)
|
2012-12-11 |
2017-09-26 |
Fluidity Software, Inc. |
Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems
|
|
AU2014209350B8
(en)
|
2013-01-23 |
2019-04-18 |
Department Of Veterans Affairs (Us) |
Targeting constructs based on natural antibodies and uses thereof
|
|
EP2970269B1
(en)
|
2013-03-14 |
2017-04-19 |
Novartis AG |
2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
JO3425B1
(ar)
|
2013-07-15 |
2019-10-20 |
Novartis Ag |
مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
|
|
EA201690247A1
(ru)
|
2013-07-18 |
2016-06-30 |
Новартис Аг |
Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
|
|
JP2016169161A
(ja)
|
2013-07-19 |
2016-09-23 |
大日本住友製薬株式会社 |
新規イミダゾピリジン化合物
|
|
AU2014306002B2
(en)
|
2013-08-07 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
|
|
US20150104445A1
(en)
|
2013-10-10 |
2015-04-16 |
Viropharma Holdings Limited |
Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
|
|
EP3089963A1
(en)
|
2013-10-30 |
2016-11-09 |
Novartis AG |
2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
|
|
HRP20200182T1
(hr)
|
2014-02-25 |
2020-05-01 |
Achillion Pharmaceuticals, Inc. |
Aril, heteroaril i heterociklični spojevi za liječenje komplementom posredovanih poremećaja
|
|
WO2016088082A1
(en)
|
2014-12-05 |
2016-06-09 |
Novartis Ag |
Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
WO2017035352A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of medical disorders
|
|
WO2017035409A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
|
WO2017035418A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for treatment of immune and inflammatory disorders
|
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
|
WO2017035357A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of medical disorders
|
|
WO2017035355A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of medical disorders
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
WO2017035417A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of immune and inflammatory disorders
|
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
|
WO2017035413A2
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
|
|
AR105808A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos de amida para el tratamiento de trastornos médicos
|
|
WO2017035348A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of medical disorders
|
|
AR105809A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos médicos
|
|
WO2017035415A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of immune and inflammatory disorders
|
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
WO2017035408A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
|
WO2017035411A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of immune and inflammatory disorders
|
|
WO2017035361A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for the treatment of medical disorders
|
|
WO2017035351A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of medical disorders
|
|
EP3386504A4
(en)
|
2015-12-11 |
2019-05-22 |
Lifesci Pharmaceuticals, Inc. |
THERAPEUTIC INHIBITOR COMPOUNDS
|
|
CN108601790B
(zh)
|
2016-01-14 |
2026-01-27 |
凯莫森特里克斯股份有限公司 |
C3肾小球病的治疗方法
|
|
EP3405577B8
(en)
|
2016-01-20 |
2023-02-15 |
396419 B.C. Ltd. |
Compositions and methods for inhibiting factor d
|
|
TWI854164B
(zh)
|
2016-02-01 |
2024-09-01 |
美商百歐克斯製藥公司 |
苯并吡唑化合物及其類似物
|
|
RU2018145364A
(ru)
|
2016-06-27 |
2020-07-28 |
Ачиллион Фармасьютикалс, Инк. |
Хиназолиновые и индольные соединения для лечения медицинских нарушений
|
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
|
EP3589287B1
(en)
|
2017-03-01 |
2022-09-14 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for treatment of medical disorders
|
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
|
CN110603252A
(zh)
|
2017-03-01 |
2019-12-20 |
艾其林医药公司 |
用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
|
|
US20190038623A1
(en)
|
2017-08-02 |
2019-02-07 |
Achillion Pharmaceuticals, Inc. |
Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
|
|
WO2019070714A1
(en)
|
2017-10-04 |
2019-04-11 |
Alexion Pharmaceuticals, Inc. |
ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
BR112021005506A2
(pt)
|
2018-09-25 |
2021-06-15 |
Achillion Pharmaceuticals, Inc. |
formas mórficas de inibidores de fator complementar d
|
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
|
KR20210104071A
(ko)
|
2018-12-17 |
2021-08-24 |
아칠리온 파르마세우티칼스 인코포레이티드 |
보체 매개 장애의 치료를 위한 표적 투약
|